Developer docs
API playgroundTry for free, no card

Search company profiles

Abolis Biotechnologies

Full company profile

uuid0000tyx

Namestring
Abolis Biotechnologies
Legal namestring
ABOLIS
Websiteurl
abolis.fr
Company typeenum
Private
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersÉvry, France
HQ citystring
Évry
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbial biotechnology solutions, strain engineering services, industrial fermentation solutions, metabolic engineering services, bio-based ingredient development
Industry5 codes
PRIMARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYAFABAEAM
Biological Formulation, Fermentation & Scale-Up Manufacturing
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Biologicals & Biopesticides (Microbials, Botanicals, Beneficial Insects)
SECONDARYEUAAAIAJ
Bio-based Food & Flavor Ingredients (Non-fuel Co-products: sweeteners, organic acids, flavors)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Industrial Organic Chemicals2860
  • Pharmaceutical Preparations2834
Product category
Industrial Biotechnology Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Custom Microbial Solutions Services
TypeProfessional Services
Description

End-to-end solutions for bio-based product innovation including strain engineering, bioprocess development, and industrial scale-up. Projects tailored to client needs across pharmaceutical, cosmetic, nutrition, and chemical industries.

abolis.fr
2Microbiome Studio SaaS
TypeSubscription Recurring
Description

Software-as-a-service platform for microbiome analysis and metabolic network visualization. Offered in two modes: full SaaS access with team training, or service mode where the Microbiome Studio team builds projects from client briefs.

abolis.fr
3Strategic Industrial Partnerships
TypeLicensing Royalties
Description

Long-term strategic partnerships with industry leaders like L'Oréal and Evonik for joint product development and commercialization across multiple sectors.

abolis.fr
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain
Pricing details2 tiers
1Microbiome Studio SaaS Mode
ModelSubscriptionBilling cadenceAnnual
Notes

Full access to Microbiome Studio platform with team training. Personalized licensing fee based on client needs.

abolis.fr
2Microbiome Studio Service Mode
ModelHybridBilling cadenceProject-based
Notes

Microbiome Studio team builds project from client brief. Analysis and dashboards generated for client with interpretation support.

abolis.fr
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Microbiome Studio
Description

A SaaS solution for analysis and visualization of metabolic networks, graphical metabolic maps, and strain/ecosystem selection for microbiome-based product innovation.

abolis.fr
Core offering1 text field

Abolis provides tailor-made industrial biosolutions based on microorganisms, delivering end-to-end microbial biotechnology services covering strain engineering, microbiome deciphering, bioprocess development, and industrial scale transfer. The company combines synthetic biology, proprietary genetic tools, fermentation technologies, and machine learning to design custom microorganisms that produce bio-based ingredients for pharmaceutical, cosmetic, nutrition, and specialty chemical applications. Its Microbiome Studio SaaS platform enables metabolic network analysis and visualization for microbiome-based product innovation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Nearly 80% of global corticosteroid market currently controlled by Asian producers, providing significant market opportunity for European production
+1 more record
Product overview1 text field

Abolis Biotechnologies offers a unified portfolio comprising two core platforms: Microbiome Studio (a SaaS solution for microbiome analysis and metabolic network visualization) and Industrial Biotech (end-to-end microbial fermentation solutions). These are supported by four integrated service modules—Strain Engineering, Microbiome Deciphering, Bioprocess Development, and Industrial Scale Transfer—that collectively enable bio-based product innovation across Healthcare, Cosmetic, Nutrition & Agriculture, and Specialty Chemicals industries. The company leverages advanced genetic tools, Machine Learning, and fermentation technologies to design custom microorganisms for sustainable and cost-effective production.

Product and service6 records
1Microbiome Studio
CategorySoftware / SaaS Platform
Description

A SaaS platform for analysis and visualization of metabolic networks, providing tools for multi-omics data processing, graphical metabolic mapping, and ML-driven strain and ecosystem selection for microbiome-based product innovation. Available in SaaS mode (self-service with own datasets) and Service mode (project built by the Microbiome Studio team). Targeted at biotech and pharmaceutical R&D teams.

2Industrial Biotech
CategoryMicrobial Biotechnology Services
Description

End-to-end microbial biotechnology solutions covering strain selection and engineering, bioprocess development, strain optimization, and industrial transfer. Supports production of bio-based ingredients through fermentation technologies for pharmaceutical, cosmetic, nutrition, and specialty chemical customers.

3Strain Engineering
CategoryMicrobial Biotechnology Services
Description

Strategic identification of high-potential strains using Abolis's proprietary strain collection and development of cutting-edge genetic tools for rapid and precise microorganism domestication. Includes initial Techno Economic Assessment to evaluate industrial viability. Targeted at companies seeking custom microbial production hosts.

4Microbiome Deciphering
CategoryMicrobial Biotechnology Services
Description

Analysis and engineering of microbial ecosystems using advanced data science and machine learning to understand strain metabolism and identify optimal candidates for microbiome-based product innovation. Targeted at biotech and industrial R&D teams developing microbiome-based products.

5Bioprocess Development
CategoryMicrobial Biotechnology Services
Description

Designing fermentation processes and nutrient media to maximize product yield, implementing real-time sensors and strong analytical platforms, and optimizing fermentation parameters at scale-up conditions. Targeted at companies scaling bio-based production processes.

6Industrial Scale Transfer
CategoryMicrobial Biotechnology Services
Description

Fermentation optimization from lab to 20L scale with trusted partners for pilot to industrial scale manufacturing, providing one-stop support from concept to commercial production of bio-based ingredients. Targeted at enterprises requiring commercial-scale fermentation capacity.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-12-01
Description

Participation in fourth edition of program strengthening technological collaborations between France and Saudi Arabia. Aligns with Saudi Vision 2030 for economic diversification and ecological transition.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-23
Description

Strategic partnership as part of IPCEI Med4Cure program (up to €140 million public support via France 2030). Abolis develops microbial strains and bioprocesses for corticosteroid production to restore European pharmaceutical sovereignty. Production at EUROAPI sites in Normandy and Auvergne. Four-year collaboration with funding from Bpifrance and EUROAPI.

3Institute of Chemistry for Health at Chimie Paris Tech
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-10-23
Description

Academic partner in Med4Cure IPCEI program bringing together innovative companies and leading academic teams for pharmaceutical sovereignty.

abolis.fr
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-10-23
Description

Academic partner in Med4Cure IPCEI program contributing to corticosteroid production development research.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-10-23
Description

Academic partner in Med4Cure IPCEI program supporting pharmaceutical innovation research.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-10-23
Description

Academic partner in Med4Cure IPCEI program contributing to pharmaceutical development expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-28
Description

Strategic partnership with Abolis and Evonik to develop bio-based ingredients for cosmetics. Goal to reduce industry carbon footprint and enhance sustainability in raw material sourcing. Involves research, development, and production of environmentally friendly ingredients. Supported by €35 million investment round.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-28
Description

Strategic partnership with L'Oréal and Abolis for developing bio-based ingredients across cosmetic, nutrition and healthcare sectors. Evonik contributes expertise in fermentation processes, downstream processing and scale-up for commercial production. Lead investor in €35 million funding round.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based strain engineering and fermentation CDMO that develops custom microorganisms to produce bio-based ingredients across food, nutrition, cosmetics and pharma. Directly comparable to Abolis in offering tailor-made microbial solutions for industrial customers.

TypeBroad incumbent
Description

Largest publicly listed synthetic biology platform, engineering microbes for industrial applications across multiple end-markets. A broader incumbent whose Cell Engineering and Biosecurity offerings overlap with Abolis's strain engineering and microbiome analytics capabilities.

TypeDirect peer
Description

Specialist in engineered enzymes and microbial strains for pharmaceutical and industrial applications. Highly comparable to Abolis in combining proprietary protein/strain engineering with bioprocess development and customer-funded scale-up.

TypeDirect peer
Description

AI-driven synthetic biology platform that designs and scales microbial fermentation for chemicals, nutrition and personal care. Closely mirrors Abolis's positioning of computational biology plus industrial fermentation for bio-based ingredients.

TypeEmerging player
Description

Amsterdam-based ML platform for protein and enzyme design sold to industrial biotech and pharma R&D teams. Adjacent to Abolis's Microbiome Studio SaaS, addressing similar ML-for-biology use cases in industrial settings.

TypeBroad incumbent
Description

Industrial biotech company commercializing gas-fermentation at scale for fuels and chemicals, with strategic partnerships across consumer goods. A broader incumbent in industrial fermentation whose commercial model mirrors Abolis's customer-funded scale-up approach.

TypeBroad incumbent
Description

Global enzyme and microbial solutions leader (post Novozymes-Christian Hansen merger) serving food, health and industrial markets. Establishes the incumbent benchmark that Abolis competes against in bio-based ingredients and fermentation services.

TypeBroad incumbent
Description

Global nutrition, health and beauty ingredients giant combining fermentation, bioprocess and formulation capabilities. A large established player whose specialty ingredients and bio-based alternatives directly overlap with Abolis's customer offerings in nutrition and cosmetics.

TypeEmerging player
Description

US cell-free biomanufacturing startup developing sustainable ingredients for cosmetics and pharma, partnered with L'Oréal. Directly comparable to Abolis in pursuing bio-based cosmetic ingredients through L'Oréal's venture and open-innovation ecosystem.

TypeEmerging player
Description

French industrial biotech using engineered enzymes for plastics recycling and bio-based polymers. A regional emerging peer with similar French biocluster presence and an industrial-biotech commercialization model comparable to Abolis's.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Abolis Biotechnologies

Industrial Biotechnology Servicesabolis.fr

Abolis Biotechnologies firmographics

Firmographics
Name
Abolis Biotechnologies
Legal name
ABOLIS
Website
https://abolis.fr
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Abolis Biotechnologies industry classification

Industry
Product category
Industrial Biotechnology Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Industrial Organic Chemicals (2860), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYAFABAEAM
Biological Formulation, Fermentation & Scale-Up Manufacturing
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Biologicals & Biopesticides (Microbials, Botanicals, Beneficial Insects)
SECONDARYEUAAAIAJ
Bio-based Food & Flavor Ingredients (Non-fuel Co-products: sweeteners, organic acids, flavors)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

  • Microbial biotechnology solutions
  • Strain engineering services
  • Industrial fermentation solutions
  • Metabolic engineering services
  • Bio-based ingredient development

Where Abolis Biotechnologies is headquartered

Location

Headquarters

HQ city
Évry
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Abolis Biotechnologies business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Custom Microbial Solutions Services: End-to-end solutions for bio-based product innovation including strain engineering, bioprocess development, and industrial scale-up. Projects tailored to client needs across pharmaceutical, cosmetic, nutrition, and chemical industries.
  2. Microbiome Studio SaaS: Software-as-a-service platform for microbiome analysis and metabolic network visualization. Offered in two modes: full SaaS access with team training, or service mode where the Microbiome Studio team builds projects from client briefs.
  3. Strategic Industrial Partnerships: Long-term strategic partnerships with industry leaders like L'Oréal and Evonik for joint product development and commercialization across multiple sectors.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualMicrobiome Studio SaaS Mode
HybridProject-basedMicrobiome Studio Service Mode

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Abolis Biotechnologies product offering

Product offering

Core offering

Abolis provides tailor-made industrial biosolutions based on microorganisms, delivering end-to-end microbial biotechnology services covering strain engineering, microbiome deciphering, bioprocess development, and industrial scale transfer. The company combines synthetic biology, proprietary genetic tools, fermentation technologies, and machine learning to design custom microorganisms that produce bio-based ingredients for pharmaceutical, cosmetic, nutrition, and specialty chemical applications. Its Microbiome Studio SaaS platform enables metabolic network analysis and visualization for microbiome-based product innovation.

Product overview

Abolis Biotechnologies offers a unified portfolio comprising two core platforms: Microbiome Studio (a SaaS solution for microbiome analysis and metabolic network visualization) and Industrial Biotech (end-to-end microbial fermentation solutions). These are supported by four integrated service modules—Strain Engineering, Microbiome Deciphering, Bioprocess Development, and Industrial Scale Transfer—that collectively enable bio-based product innovation across Healthcare, Cosmetic, Nutrition & Agriculture, and Specialty Chemicals industries. The company leverages advanced genetic tools, Machine Learning, and fermentation technologies to design custom microorganisms for sustainable and cost-effective production.

Differentiator

Problem solved

Functional benefit

Brands

  • Microbiome Studio: A SaaS solution for analysis and visualization of metabolic networks, graphical metabolic maps, and strain/ecosystem selection for microbiome-based product innovation.

Products and services

  • Microbiome Studio A SaaS platform for analysis and visualization of metabolic networks, providing tools for multi-omics data processing, graphical metabolic mapping, and ML-driven strain and ecosystem selection for microbiome-based product innovation. Available in SaaS mode (self-service with own datasets) and Service mode (project built by the Microbiome Studio team). Targeted at biotech and pharmaceutical R&D teams.
  • Industrial Biotech End-to-end microbial biotechnology solutions covering strain selection and engineering, bioprocess development, strain optimization, and industrial transfer. Supports production of bio-based ingredients through fermentation technologies for pharmaceutical, cosmetic, nutrition, and specialty chemical customers.
  • Strain Engineering Strategic identification of high-potential strains using Abolis's proprietary strain collection and development of cutting-edge genetic tools for rapid and precise microorganism domestication. Includes initial Techno Economic Assessment to evaluate industrial viability. Targeted at companies seeking custom microbial production hosts.
  • Microbiome Deciphering Analysis and engineering of microbial ecosystems using advanced data science and machine learning to understand strain metabolism and identify optimal candidates for microbiome-based product innovation. Targeted at biotech and industrial R&D teams developing microbiome-based products.
  • Bioprocess Development Designing fermentation processes and nutrient media to maximize product yield, implementing real-time sensors and strong analytical platforms, and optimizing fermentation parameters at scale-up conditions. Targeted at companies scaling bio-based production processes.
  • Industrial Scale Transfer Fermentation optimization from lab to 20L scale with trusted partners for pilot to industrial scale manufacturing, providing one-stop support from concept to commercial production of bio-based ingredients. Targeted at enterprises requiring commercial-scale fermentation capacity.

Quantifiable outcome

  • Nearly 80% of global corticosteroid market currently controlled by Asian producers, providing significant market opportunity for European production
  • +1 more outcomes

Companies that use Abolis Biotechnologies

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles5 records

Abolis Biotechnologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Abolis Biotechnologies partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor, core and supporting.

  • Booster Grow Global KSAminorGTM or Marketing Partner · 1 December 2025Participation in fourth edition of program strengthening technological collaborations between France and Saudi Arabia. Aligns with Saudi Vision 2030 for economic diversification and ecological transition.
  • EUROAPIcoreStrategic or Co-development Partner · 23 October 2025Strategic partnership as part of IPCEI Med4Cure program (up to €140 million public support via France 2030). Abolis develops microbial strains and bioprocesses for corticosteroid production to restore European pharmaceutical sovereignty. Production at EUROAPI sites in Normandy and Auvergne. Four-year collaboration with funding from Bpifrance and EUROAPI.
  • Institute of Chemistry for Health at Chimie Paris TechsupportingStrategic or Co-development Partner · 23 October 2025Academic partner in Med4Cure IPCEI program bringing together innovative companies and leading academic teams for pharmaceutical sovereignty.
  • CARMEN laboratory at INSA RouensupportingStrategic or Co-development Partner · 23 October 2025Academic partner in Med4Cure IPCEI program contributing to corticosteroid production development research.
  • CEISAM laboratory at University of NantessupportingStrategic or Co-development Partner · 23 October 2025Academic partner in Med4Cure IPCEI program supporting pharmaceutical innovation research.
  • Toulouse INPsupportingStrategic or Co-development Partner · 23 October 2025Academic partner in Med4Cure IPCEI program contributing to pharmaceutical development expertise.
  • L'OréalcoreStrategic or Co-development Partner · 28 September 2024Strategic partnership with Abolis and Evonik to develop bio-based ingredients for cosmetics. Goal to reduce industry carbon footprint and enhance sustainability in raw material sourcing. Involves research, development, and production of environmentally friendly ingredients. Supported by €35 million investment round.
  • EvonikcoreStrategic or Co-development Partner · 28 September 2024Strategic partnership with L'Oréal and Abolis for developing bio-based ingredients across cosmetic, nutrition and healthcare sectors. Evonik contributes expertise in fermentation processes, downstream processing and scale-up for commercial production. Lead investor in €35 million funding round.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Abolis Biotechnologies competitors and assessment

Company assessment

Direct peers

  • Conagen: US-based strain engineering and fermentation CDMO that develops custom microorganisms to produce bio-based ingredients across food, nutrition, cosmetics and pharma. Directly comparable to Abolis in offering tailor-made microbial solutions for industrial customers.
  • Codexis: Specialist in engineered enzymes and microbial strains for pharmaceutical and industrial applications. Highly comparable to Abolis in combining proprietary protein/strain engineering with bioprocess development and customer-funded scale-up.
  • Bota Bio: AI-driven synthetic biology platform that designs and scales microbial fermentation for chemicals, nutrition and personal care. Closely mirrors Abolis's positioning of computational biology plus industrial fermentation for bio-based ingredients.

Broad incumbents

  • Ginkgo Bioworks: Largest publicly listed synthetic biology platform, engineering microbes for industrial applications across multiple end-markets. A broader incumbent whose Cell Engineering and Biosecurity offerings overlap with Abolis's strain engineering and microbiome analytics capabilities.
  • LanzaTech: Industrial biotech company commercializing gas-fermentation at scale for fuels and chemicals, with strategic partnerships across consumer goods. A broader incumbent in industrial fermentation whose commercial model mirrors Abolis's customer-funded scale-up approach.
  • Novonesis: Global enzyme and microbial solutions leader (post Novozymes-Christian Hansen merger) serving food, health and industrial markets. Establishes the incumbent benchmark that Abolis competes against in bio-based ingredients and fermentation services.
  • dsm-firmenich: Global nutrition, health and beauty ingredients giant combining fermentation, bioprocess and formulation capabilities. A large established player whose specialty ingredients and bio-based alternatives directly overlap with Abolis's customer offerings in nutrition and cosmetics.

Emerging players

  • Cradle: Amsterdam-based ML platform for protein and enzyme design sold to industrial biotech and pharma R&D teams. Adjacent to Abolis's Microbiome Studio SaaS, addressing similar ML-for-biology use cases in industrial settings.
  • Debut Biotech: US cell-free biomanufacturing startup developing sustainable ingredients for cosmetics and pharma, partnered with L'Oréal. Directly comparable to Abolis in pursuing bio-based cosmetic ingredients through L'Oréal's venture and open-innovation ecosystem.
  • Carbios: French industrial biotech using engineered enzymes for plastics recycling and bio-based polymers. A regional emerging peer with similar French biocluster presence and an industrial-biotech commercialization model comparable to Abolis's.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Abolis Biotechnologies social profiles

Digital presence

Abolis Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Abolis Biotechnologies leadership team

Management profile

Number of profiles

Profiles6 records

Abolis Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Abolis Biotechnologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abolis Biotechnologies

What does Abolis Biotechnologies do?

Abolis provides tailor-made industrial biosolutions based on microorganisms, delivering end-to-end microbial biotechnology services covering strain engineering, microbiome deciphering, bioprocess development, and industrial scale transfer. The company combines synthetic biology, proprietary genetic tools, fermentation technologies, and machine learning to design custom microorganisms that produce bio-based ingredients for pharmaceutical, cosmetic, nutrition, and specialty chemical applications. Its Microbiome Studio SaaS platform enables metabolic network analysis and visualization for microbiome-based product innovation.

Is Abolis Biotechnologies a public or private company?

Abolis Biotechnologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Abolis Biotechnologies founded?

Abolis Biotechnologies was founded in 2014. It employs 51 to 100 people.

Where is Abolis Biotechnologies based?

Abolis Biotechnologies is headquartered in Évry, France, in the Europe region.

How does Abolis Biotechnologies make money?

Three revenue lines are on record. Custom Microbial Solutions Services are the primary driver. The others are microbiome Studio SaaS and strategic Industrial Partnerships.

Who are Abolis Biotechnologies's main competitors?

Direct peers on record are Conagen, Codexis and Bota Bio. Broad incumbents are Ginkgo Bioworks, LanzaTech, Novonesis and dsm-firmenich. Emerging players are Cradle, Debut Biotech and Carbios.

Does Abolis Biotechnologies have an API?

No public API is recorded for Abolis Biotechnologies.

What industry is Abolis Biotechnologies in?

Abolis Biotechnologies's product category is Industrial Biotechnology Services. Its primary akta.pro industry code is HLAAAFAJ, Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery), with a secondary code of HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms. Its NAICS code is 541714 and its SIC code is 2860.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Cosmetics BusinessAbolis Biotechnologies’ new platform boosts discovery of microbial-derived cosmetic ingredientsAbolis Biotechnologies launched MINE, a platform to accelerate discovery of microbial-derived cosmetic ingredients. It integrates multi-omics data with experimental insights to help R&D teams navigate microbial systems. The tool was built on Microbiome Studio and aims to make microbial biotechnology more industrially available.BioSpaceAbolis Biotechnologies and EUROAPI Enter Into Partnership to Accelerate Pharmaceutical Innovation and Restore European SovereigntyAbolis Biotechnologies and EUROAPI have announced a strategic partnership to develop microbial strains for synthesizing corticosteroids and 20 active pharmaceutical ingredients, aiming to reduce Europe's reliance on Asian manufacturers in a sector where nearly 80% of global production is currently controlled by China and India. The partnership is part of the Med4Cure program under the European IPCEI initiative, backed by up to €140 million in public support through Bpifrance as part of France 2030, with production to be distributed between EUROAPI's sites in Normandy and Auvergne. The initiative addresses structural vulnerabilities in European pharmaceutical supply chains that have led to recurring shortages, positioning the collaboration as a step toward restoring European pharmaceutical sovereignty.Business Wire BlogAbolis Biotechnologies and EUROAPI Enter Into Partnership to Accelerate Pharmaceutical Innovation and Restore European SovereigntyAbolis Biotechnologies and EUROAPI have entered a strategic partnership to develop microbial bioprocesses for producing corticosteroids in Europe, aiming to reduce reliance on Asian manufacturers. The collaboration is part of the Med4Cure program under the European IPCEI framework, backed by up to €140 million in public support through Bpifrance and France 2030. This initiative seeks to restore European pharmaceutical sovereignty by bringing production of these essential drugs, currently facing recurring supply shortages, back to European facilities at competitive costs.Precedence ResearchBiotech Ingredients Market Size to Hit USD 5.10 Billion by 2034The global biotech ingredients market is projected to grow from USD 2.40 billion in 2024 to USD 5.10 billion by 2034, representing a compound annual growth rate of 7.83%, driven by advancements in biotechnology and increasing demand for sustainable, bio-based alternatives. Europe currently leads the market with a 38% share in 2024, while Asia Pacific is expected to grow at the highest CAGR through 2034. Recent industry activity includes L'Oréal's partnership with Debut Biotech and Abolis Biotechnologies to develop sustainable ingredients, and Sensient Technologies' acquisition of French manufacturer Biolie in February 2025.of Procurement & Supply Chain NewsL'Oréal's Biotech Venture to Reshape Cosmetics Supply ChainL'Oréal has entered into a strategic partnership with Abolis Biotechnologies and Evonik Industries to develop bio-based ingredients for cosmetics, aiming to reduce the industry's carbon footprint and enhance sustainability in raw material sourcing. The collaboration involves research, development, and production of environmentally friendly ingredients, supported by a significant investment round for Abolis. This initiative aligns with L'Oréal's broader sustainability goals, including sourcing from circular processes and powering sites with renewable energy.EuropaWireInternational Consortium Invests €35 Million in Abolis Biotechnologies for Sustainable GrowthAbolis Biotechnologies secured €35 million from a global consortium including Evonik Venture Capital, BOLD, and the DeepTech & Climate Fonds. The funding will expand its biomanufacturing and bring sustainable biobased products to healthcare, cosmetics, and chemicals. The company also signed a strategic partnership with L'Oréal and Evonik to accelerate innovation.cosmeticsdesign-europe.comL'Oréal tri-partnership for “new generation of bio-based ingredients”L'Oréal Groupe signed a tri-party agreement with Abolis Biotechnologies and Evonik to develop bio-based ingredients. L'Oréal invested over €1bn in R&D annually and participated in Abolis's €35m Series A. The partnership aims to produce sustainable ingredients at scale for global demand.YahooAbolis Biotechnologies Secures 35 Mio. Euro From International Consortium of Industrials and FundsAbolis Biotechnologies closed a €35 million financing round led by an international consortium including L'Oréal's BOLD, Evonik Venture Capital, and DeepTech & Climate Fonds. The funds will support global expansion and R&D, and the company signed a tri-party agreement with L'Oréal and Evonik for strategic projects.Business Wire BlogAbolis Biotechnologies Secures 35 Mio. Euro From International Consortium of Industrials and FundsAbolis Biotechnologies closed a €35 million financing round led by an international consortium including BOLD, Evonik, and DeepTech & Climate Fonds. The funds will support global expansion, R&D, and a new strategic partnership with L'Oréal and Evonik. The company previously raised €1.1 million since 2014.